Skip to Main Content
Table 2.

Tumor levels of total cAMP in response to increasing light intensities during darkness

Light intensity (μW/cm2)Tumor cAMP concentration (nmol/g)
Rat hepatoma 7288CTCSR MCF-7 human breast cancer xenografts
Dark 0.18 ± 0.01 0.02 ± 0.0 
0.02 0.45 ± 0.06* 0.09 ± 0.01 
0.05 0.50 ± 0.06* 0.27 ± 0.01 
0.06 0.53 ± 0.03* 0.26 ± 0.03 
0.08 0.48 ± 0.03* 0.31 ± 0.04 
Constant light, 345 0.72 ± 0.04 0.33 ± 0.03§ 
Light intensity (μW/cm2)Tumor cAMP concentration (nmol/g)
Rat hepatoma 7288CTCSR MCF-7 human breast cancer xenografts
Dark 0.18 ± 0.01 0.02 ± 0.0 
0.02 0.45 ± 0.06* 0.09 ± 0.01 
0.05 0.50 ± 0.06* 0.27 ± 0.01 
0.06 0.53 ± 0.03* 0.26 ± 0.03 
0.08 0.48 ± 0.03* 0.31 ± 0.04 
Constant light, 345 0.72 ± 0.04 0.33 ± 0.03§ 

NOTE: Effects of exposure of rats bearing either hepatoma 7288CTC (male rats) or SR MCF-7 human breast cancer xenografts (nude female rats) to increasing intensities of light during the entire dark phase (12 hours) of a 12-hour light/12-hour dark cycle on tumor cAMP concentrations. At the end of the growth period for each of the light treatment groups, tumors were freeze-clamped under liquid N2 and then assayed for cAMP via an ELISA. See Figs. 2 and 3 legends for further details. Value are means ± SE; n = 6 rats (tumors per group).

*

P < 0.05, hepatoma vs dark control.

P < 0.05, breast vs dark control (except 0.08 μW/cm2).

P < 0.05, hepatoma vs all other groups.

§

P < 0.05, breast vs all other groups (except 0.08 μW/cm2).

Close Modal

or Create an Account

Close Modal
Close Modal